{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:23:46Z","timestamp":1768094626382,"version":"3.49.0"},"reference-count":55,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Coagulation disorders are increasingly recognized as significant complications in patients with solid tumors, affecting morbidity and mortality outcomes. Solid tumors can provoke a hypercoagulable state through the release of pro-coagulant factors, endothelial activation, and inflammation, leading to a heightened risk of coagulation disorders. These coagulation disorders may manifest as venous thromboembolism, arterial thromboembolism, thrombotic microangiopathy, or disseminated intravascular coagulation. These disorders can complicate surgical interventions and impact treatments, including chemotherapy and immunotherapy efficacy, leading to poor outcomes. Understanding the implications of coagulation disorders in solid tumors is essential for optimizing patient management, including identifying high-risk patients, implementing prophylactic measures, elucidating biomarkers for clinical outcomes, and exploring novel therapeutic agents. This review aims to provide insights into the current knowledge surrounding coagulation disorders in solid tumors and their clinical implications.<\/jats:p>","DOI":"10.3390\/hematolrep17010008","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:44:59Z","timestamp":1738741499000},"page":"8","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Solid Tumors, Liquid Challenges: The Impact of Coagulation Disorders"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-1575","authenticated-orcid":false,"given":"Nidha","family":"Shapoo","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College, Metropolitan Hospital, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noella","family":"Boma","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Metropolitan Hospital, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobhana","family":"Chaudhari","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Metropolitan Hospital, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Gotlieb","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Metropolitan Hospital, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-030-20315-3_2","article-title":"Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients","volume":"179","author":"Falanga","year":"2019","journal-title":"Cancer Treat. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.critrevonc.2017.08.003","article-title":"Mechanisms and risk factors of thrombosis in cancer","volume":"118","author":"Falanga","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis","volume":"45","author":"Rondon","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: Biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102322","DOI":"10.1016\/j.ctrv.2021.102322","article-title":"Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities","volume":"102","author":"Bauer","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tawil, N., Mohammadnia, A., and Rak, J. (2023). Oncogenes and cancer associated thrombosis: What can we learn from single cell genomics about risks and mechanisms?. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1252417"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaccao.2023.03.002","article-title":"Tumor Genetics Are Thrombogenic: The Need for Action","volume":"5","author":"Elalamy","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1054\/blre.2001.0149","article-title":"Cancer and thrombosis revisited","volume":"15","author":"Hoffman","year":"2001","journal-title":"Blood Rev."},{"key":"ref_9","first-page":"684","article-title":"Cancer-associated thrombosis","volume":"2013","author":"Connolly","year":"2013","journal-title":"Hematol. ASH Educ. Prog."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1040-8428(03)00041-6","article-title":"Venous thromboembolism and cancer: New issues for an old topic","volume":"48","author":"Mandala","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"Sorensen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1055\/s-0037-1616139","article-title":"Disseminated intravascular coagulation in solid tumors: Clinical and pathologic study","volume":"86","author":"Sallah","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lima, L.G., and Monteiro, R.Q. (2013). Activation of blood coagulation in cancer: Implications for tumor progression. Biosci. Rep., 33.","DOI":"10.1042\/BSR20130057"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: Risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1076029620975484","DOI":"10.1177\/1076029620975484","article-title":"Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study","volume":"27","author":"Peng","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing Risk of Venous Thromboembolism in the Patient With Cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.22.00255","article-title":"A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts","volume":"41","author":"Ay","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2023.3634","article-title":"Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial","volume":"9","author":"Alexander","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Xu, Y., Carrier, M., and Kimpton, M. (2024). Arterial Thrombosis in Patients with Cancer. Cancers, 16.","DOI":"10.3390\/cancers16122238"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Abdol Razak, N.B., Jones, G., Bhandari, M., Berndt, M.C., and Metharom, P. (2018). Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers, 10.","DOI":"10.3390\/cancers10100380"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.mayocp.2021.01.013","article-title":"Arterial Thrombosis and Cancer: Implications for Screening and Risk Modification","volume":"96","author":"McBane","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11936-018-0635-x","article-title":"Arterial Thrombosis in Patients with Cancer","volume":"20","author":"Tuzovic","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaccao.2023.01.009","article-title":"Tumor Genomic Profile Is Associated with Arterial Thromboembolism Risk in Patients with Solid Cancer","volume":"5","author":"Feldman","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of Arterial Thromboembolism in Patients with Cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jstrokecerebrovasdis.2008.01.007","article-title":"First-ever stroke as initial presentation of systemic cancer","volume":"17","author":"Taccone","year":"2008","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/jnnp.2006.092940","article-title":"Ischemic stroke with malignancy may often be caused by paradoxical embolism","volume":"77","author":"Iguchi","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaccao.2023.04.003","article-title":"Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients: Systematic Review and Meta-Analysis","volume":"5","author":"Xu","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1007\/s00520-022-06935-5","article-title":"Thrombotic microangiopathy (TMA) in adult patients with solid tumors: A challenging complication in the era of emerging anticancer therapies","volume":"30","author":"Font","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and Outcomes of Thrombotic Microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101081","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic microangiopathy in oncology\u2014A review","volume":"14","author":"Barreto","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5414\/CNCS109836","article-title":"Eculizumab in chemotherapy-induced thrombotic microangiopathy","volume":"8","author":"Reister","year":"2020","journal-title":"Clin. Nephrol. Case Stud."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1440-1746.2010.06289.x","article-title":"Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study","volume":"25","author":"Rhee","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3949\/ccjm.72.5.377","article-title":"Disseminated intravascular coagulation: Treat the cause, not the lab values","volume":"72","author":"Labelle","year":"2005","journal-title":"Cleve Clin. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(16)30101-3","article-title":"Management of cancer-associated disseminated intravascular coagulation","volume":"140","author":"Levi","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3960\/jslrt.51.67","article-title":"Diagnostic criteria and laboratory tests for disseminated intravascular coagulation","volume":"51","author":"Kaneko","year":"2011","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1538-7836.2007.02313.x","article-title":"The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: A 5-year overview","volume":"5","author":"Toh","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2050312117749133","DOI":"10.1177\/2050312117749133","article-title":"Understanding and treating solid tumor-related disseminated intravascular coagulation in the \u201cera\u201d of targeted cancer therapies","volume":"5","author":"Vitale","year":"2017","journal-title":"SAGE Open Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1111\/jth.15880","article-title":"Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer","volume":"20","author":"Moik","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","article-title":"Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Bethune","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: The FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/1\/8\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:27:13Z","timestamp":1760027233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["hematolrep17010008"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17010008","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}